| Pluristem Therapeutics develops placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries and hematologic conditions. Co.'s product candidates include: Placenta expanded (PLX)-peripheral arterial disease, which is used in recovery following surgery for hip fracture, in Acute Respiratory Distress Syndrome associated with COVID-19 and Intermittent Claudication, and used in for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease; and PLX-R18, which is used in incomplete hematopoietic recovery following hematopoietic cell transplantation and Acute Radiation Syndrome following or before exposure to massive radiation. We show 52 historical shares outstanding datapoints in our coverage of PSTI's shares outstanding history.
Understanding the changing numbers of PSTI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PSTI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PSTI by allowing them to research PSTI shares outstanding history
as well as any other stock in our coverage universe.